Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Medidata launches open-source connector linking Apple ResearchKit to Medidata Clinical Cloud

Wednesday, May 6, 2015 02:52 PM

Medidata, a global provider of cloud-based solutions for clinical research in life sciences, has completed an open-source connector linking Apple ResearchKit with the Medidata Clinical Cloud platform. This mechanism will enable life sciences companies and academic institutions to map data generated by ResearchKit apps into Medidata's secure, regulatory-compliant environment, integrating the data with other information collected in clinical trials.

More... »

Quest Diagnostics

Teva provides additional detail on proposed acquisition of Mylan

Wednesday, May 6, 2015 02:51 PM

Teva Pharmaceutical Industries has released an updated investor presentation in connection with its proposed combination with Mylan, which will be filed with the Securities and Exchange Commission (SEC).

More... »


Flagship Ventures partners with AstraZeneca, Nestlé, Bayer

Wednesday, May 6, 2015 02:48 PM

Flagship Ventures, a venture capital and venture creation firm focused on innovations in healthcare and sustainability, has formed strategic innovation partnerships with AstraZenecaNestlé Health Science and Bayer CropScience. These collaborations will allow Flagship to scale up its unique innovation foundry, VentureLabs, as well as expand its early stage venture funding activities while leveraging the partners' strengths as market leaders.

More... »

OPKO Health acquires EirGen Pharma

Wednesday, May 6, 2015 02:46 PM

OPKO Health, a multinational biopharmaceutical and diagnostics company, has acquired EirGen Pharma, a specialty pharmaceutical company focused on the development and commercial supply of high-potency, high-barrier-to-entry pharmaceutical products for sale in the U.S., Canada, Japan, Australia, most European countries and more than 40 others around the world.

More... »

Tobira Therapeutics completes merger with Regado Biosciences

Wednesday, May 6, 2015 02:45 PM

Tobira Therapeutics, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and immuno-inflammatory diseases, has merged with Regado Biosciences. Tobira raised $40 million of common stock from a combination of new investors and all current Tobira institutional investors, including the previously announced $13 million in debt that converted to common stock in this closing. Together with approximately $33 million net cash on Regado's balance sheet, the combined company has approximately $70 million in cash to advance clinical development of first-in-class dual CCR2/CCR5 inhibitor cenicriviroc (CVC), which is being evaluated in the phase IIb CENTAUR clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis.

More... »

ArQule, Beryllium collaborate

Wednesday, May 6, 2015 02:44 PM

ArQule, a Woburn, Mass.-based biotechnology company, and Beryllium Discovery, a company using target-centric platforms to provide research services and collaborations to commercial and academic partners, have formed a collaborative R&D agreement to identify and unlock the therapeutic potential of small molecule compounds by combining ArQule’s chemistry and drug development experience with Beryllium’s discovery platforms. The Beryllium platforms integrate structure-guided drug discovery, biophysics and cell biology.

More... »

Teva completes acquisition of Auspex Pharmaceuticals

Wednesday, May 6, 2015 02:39 PM

Teva Pharmaceutical Industries has completed the acquisition of Auspex Pharmaceuticals through the successful tender offer for all of the outstanding shares of common stock of Auspex at $101 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. The acquisition is expected to enhance Teva’s revenue and earnings growth profile and strengthen its core central nervous system franchise. Auspex now is a wholly owned subsidiary of Teva.

More... »

CytRx’s Aldoxorubicin shows improved QoL in chemotherapy resistant cancers

Monday, May 4, 2015 02:33 PM

CytRx, a biopharmaceutical R&D company specializing in oncology, has announced an interim analysis from its two ongoing phase Ib aldoxorubicin combination studies pairing aldoxorubicin with either gemcitabine or ifosfamide. Both studies combine standard doses of gemcitabine or ifosfamide with escalating doses of aldoxorubicin. The combinations appear to be well-tolerated, and even at the lowest dose level of aldoxorubicin (170mg/m2), impressive tumor responses have been observed so far in patients with bone cancer (osteosarcoma) and a variety of soft tissue sarcomas. As such, aldoxorubicin has the potential when used in combination with other cancer agents to become an important new weapon against chemotherapy resistant cancers.

More... »

Can-Fite subsidiary OphthaliX to acquire Improved Vision Systems

Monday, May 4, 2015 01:25 PM

Can-Fite BioPharma, an Israeli biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, has announced its subsidiary, OphthaliX, has signed a non-binding term sheet to acquire Israel-based Improved Vision Systems (IVS).

More... »

FPWR, NORD launch Global Prader-Willi Syndrome Registry

Monday, May 4, 2015 01:23 PM

The Foundation for Prader-Willi Research (FPWR), a nonprofit charitable organization, and National Organization for Rare Disorders (NORD), a nonprofit organization representing all patients and families affected by rare diseases in the U.S., have launched the Global Prader-Willi Syndrome Registry, a new database to accelerate research and cures for the rare disease Prader-Willi Syndrome (PWS).

More... »

CWWeekly

May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs